Epidemiology of monoclonal gammopathy in Morocco – A hospital‐based study
Cancer Reports · 2023
DOI: 10.1002/cnr2.1814 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2023. Verfasst von Zohra Ouzzif und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Pharmacy, The Military Hospital Instruction Mohamed V/Mohamed V University, Rabat, Morocco. Hauptthemen laut MEDLINE: Paraproteinemias, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Waldenstrom Macroglobulinemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Monoclonal gammopathies are a group of disorders associated with clonal proliferation of plasma cells that produces a monoclonal protein.
Aims
The main objective of this study was to describe the epidemiological and immunochemical characteristics of monoclonal gammopathies diagnosed during 19 years in a Moroccan teaching hospital. Materials and Results This retrospective study enrolled 443 Moroccan patients with monoclonal gammopathy, patients meeting the inclusion and exclusion criteria in at the biochemistry department of Military Hospital in Rabat, the capital of Morocco, from January 2000 to August 2019. Of the 443 enrolled patients, 320 (72.23%) were men and 123 (27.77%) were women. All patients were of Caucasian origin, from 12 Moroccan regions. The patient's samples were collected and subjected to serum protein electrophoresis and serum immunofixation electrophoresis to further characterize the monoclonal protein. The mean ± SD age of the 443 participants was 62.24 ± 13.14 years. Reasons for being admitted to the hospital were as follows, bone pain (41.60%), renal failure (19.08%), alteration of the general condition (12.21%), and anemia (10.69). Plasma cell proliferative disorders in our study were as follows, multiple myeloma (MM) (45.65%), Monoclonal gammopathies of undetermined significance (MGUS) (39.05%), Waldenstrom's macroglobulinemia (5.58%), Lymphoma (2.27% + 1.2%), Chronic Lymphocytic Leukemia (2.48%), Plasma cell leukemia (1.86%), Plasmacytoma (0.62%), POEMS syndrome (0.41%), and Amyloidosis (0.84%). The most frequent isotypes in MM were the IgGκ (62) 36.5%, IgGλ (52) 30.6%, IgAκ (27) 15.9%, and the IgAλ (19) 11.2%. It is also worth noting that Free light chain MM represents 20% of all cases of MM.
Conclusions
We found that monoclonal gammopathies are age‐related and affects men more than women, also the results of this study point to the delayed diagnosis of monoclonal gammopathies, since most of our patients were diagnosed at the MM stage. The most frequent isotypes were the IgGκ and IgGλ in MM and MGUS, in Waldenström macroglobulinemia were IgMκ and IgMλ and the oligoclonal profile represented only 3.70%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine and Pharmacy, The Military Hospital Instruction Mohamed V/Mohamed V University, Rabat, Morocco.
- Clinical Chemistry Department, Faculty of Medicine and Pharmacy, Ibn Zohr University, Agadir Teaching Hospital, Agadir, Morocco.
ORCID-Profile: Aissam El Maataoui
Zitieren
APA
Ouzzif, Z., Doghmi, K., Messaoudi, N., Bouhsain, S., El Machtani, S., Biaz, A., Rachid, A., Dami, A., Bezza, A., & El Maataoui, A. (2023). Epidemiology of monoclonal gammopathy in Morocco – A hospital‐based study. Cancer Reports. https://doi.org/10.1002/cnr2.1814
Vancouver
Ouzzif Z, Doghmi K, Messaoudi N, Bouhsain S, El Machtani S, Biaz A, et al. Epidemiology of monoclonal gammopathy in Morocco – A hospital‐based study. Cancer Reports. 2023. doi:10.1002/cnr2.1814
BibTeX
@article{Ouzzif2023,
author = {Ouzzif, Zohra and Doghmi, Kamal and Messaoudi, Nezha and Bouhsain, Sanae and El Machtani, Samira and Biaz, Asmae and Rachid, Achraf and Dami, Abdallah and Bezza, Ahmed and El Maataoui, Aissam},
title = {Epidemiology of monoclonal gammopathy in Morocco – A hospital‐based study},
journal = {Cancer Reports},
year = {2023},
doi = {10.1002/cnr2.1814}
}
EUVIMED